IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the...
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development...
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August...
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during...
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: About Infant Bacterial...
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application...